Chief executive officer

Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. He brings extensive strategic and operational expertise to Nusano, including licensing, financing and acquisitions. As CEO, Chris is responsible for setting the company’s strategic direction and overseeing key priorities.

Prior to Nusano, Lowe served as Chief Financial Officer and Chief Operating Officer of Cortexyme, Inc., a biotech company focused on Alzheimer’s and neurodegenerative diseases. There, he led the company’s IPO in 2019, oversaw a cash injection via a PIPE (private investment in public equity) in 2020, and guided the company’s eventual acquisition by Novosteo. Lowe holds a bachelor’s degree in Business from California Polytechnic State University, and an MBA in Finance from St. Mary’s University.

Chief Operations Officer

Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine at Cedar Sinai Medical Center. His broad experience includes time as an academic physician and as president of two nuclear medicine businesses. Dr. Lewin built a large nuclear cardiology practice with offices in several states, and a successful cardiac PET business providing state-of-the art cardiac imaging.

Dr. Lewin is widely recognized for his contributions to Nuclear Cardiology and serves as an officer of the American Society of Nuclear Cardiology, the Society of Nuclear Medicine Cardiovascular Council, the Intersocietal Accreditation Commission for Nuclear Medicine/PET, and the Certification Council for Cardiovascular Imaging. He brings with him rich relationships in the radioisotope production and distribution sectors.

Chief Technology Officer

Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer. He is an expert in accelerated particle physics, isotope target design, and radioisotope specification and production processes. While at UCLA, Dr. Rosenthal was the Principal Investigator for a number of successful projects sponsored by the NSF, DARPA, the DOE, Siemens Nuclear Power, and others.

Prior to Nusano, Dr. Rosenthal worked at Nonlinear Ion Dynamics (NID), a private company established to commercialize technology he developed and patented while at UCLA. At NID, Dr. Rosenthal was awarded a grant from the NIH to develop an isotope separation method he invented. Dr. Rosenthal is author of a number of technical publications and holds several patents.

Chief operations officer

Alexandre Gibim is an experienced pharmaceutical executive. His career spans multiple business functions and geographies, including full P&L responsibility in the United States, China, Canada, and Brazil at some of the world’s largest pharmaceutical companies. In these roles he led successful business transformation initiatives, created go-to-market strategies, built professional account management programs, and managed acquisition and divestment activities. He has a proven track record of leading teams with more than 2,000 people and has driven significant revenue growth in excess of USD $1 billion. 

Most recently, Gibim was Senior VP, Head of North America, at Advanced Accelerator Applications, a Novartis company, where he orchestrated the successful U.S. launch of 177Lu-PSMA-617 (marketed as Pluvicto™), an innovative radiopharmaceutical for prostate cancer. This pioneering treatment has achieved widespread adoption and is significantly enhancing the lives of patients through transformative outcomes.